Guided by assessing the presence of FcγR-expressing immune effector cells in the breast cancer TME, including NAC- and immunotherapy-resistant disease, we designed and evaluated Fc-engineered antibodies with enhanced affinity for the prominently expressed FcγRIIIa. The gene discussed is FCGR3A; the disease is breast carcinoma.